ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
PATIENT SATISFACTION WITH ORAL TESTOSTERONE UNDECANOATE IN TESTOSTERONE-DEFICIENT MEN WITH PREVIOUS TESTOSTERONE THERAPY
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 261248" data-attributes="member: 13851"><p>Did you even look over the original paper 8/12/22 from my thread 9/6/22 that I linked up in <strong><em>post #4.</em></strong></p><p></p><p>Notice the number of patients from week 1--->4--->14--->27.</p><p></p><p>There was a dose titration at week 4 (follow-up visit) in 24% of the patients (N=35).</p><p></p><p><strong><em>*24% of patients required uptitration, while none required downtitration</em></strong></p><p><strong><em></em></strong></p><p><strong><em>[ATTACH=full]35393[/ATTACH]</em></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong>Key points:</strong></p><p><strong></strong></p><p><strong><em>*While the study features of close bloodwork follow-up and mandatory titration allowed for medical optimization, <u>twice-daily doses were far more frequent for the oral form</u> in comparison to intramuscular and pellet therapies<u> and posed a higher risk of missed doses and poorer compliance</u></em></strong></p><p><strong><em></em></strong></p><p><strong><em>* The reason most often cited for dropout was an <u>unsatisfactory symptom response</u></em></strong></p><p><strong><em></em></strong></p><p><strong><em>*Closer examination of the results revealed that individuals who were previously receiving testosterone pellets or nasal testosterone were <u>more satisfied than patients in the intramuscular testosterone cypionate arm</u></em></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong>3. Results </strong></p><p></p><p><em>Of the <strong>41 patients enrolled in the study,</strong> 46% were previously on subdermal pellets, 41% on intramuscular injections, and 13% on nasal gels. <strong>Testosterone levels increased from a baseline median of 192.0 ng/dl to 738.5 ng/dl (618.3–896.8) at 1 mo, 481.5 ng/dl (349.3–646.3) at 14 wk, and 575.0 ng/dl (336.0–680.5) at 6 mo. Some 24% of patients required uptitration, while none required downtitration. </strong>Patient satisfaction on oral TU in terms of TSQM-9 scores increased from 42.0 (34.0–51.0) on the prior TTh to 49.0 (39.0–57.0) at 14 wk (p = 0.02) and 55.0 (52.0–59.0) at 6 mo (p = 0.0013).</em></p><p><em></em></p><p><em>Closer examination of the results revealed that individuals who were previously receiving testosterone pellets or nasal testosterone were more satisfied than patients in the intramuscular testosterone cypionate arm. <strong>Hypogonadal symptoms in terms of qADAM scores were regarded as similar at 34.4 at 14 wk (p = 0.16) and 35 at 6 mo (p = 0.83) in comparison to 32.5 on prior testosterone therapy. <u>The reason most often cited for dropout was an unsatisfactory symptom response</u>.</strong> We evaluated changes in HCT, prostate-specific antigen, and serum estradiol after testosterone therapy and found that the levels were similar before and after TTh. Of note, phlebotomy was recommended for 16% of the men during the trial.</em></p><p></p><p></p><p><strong>4. Discussion </strong></p><p></p><p><em>This is the first study investigating patient satisfaction among men receiving oral TU who were previously using other forms of TTh. <strong>Over the course of the trial, oral TU appeared to lead to greater patient satisfaction in comparison to previous TTh modalities and a similar improvement in hypogonadal symptoms. In addition, oral TU increased serum total testosterone to the normal range (300–1000 ng/dl) in >90% of the men without a difference in side effect profile. <u>While the study features of close bloodwork follow-up and mandatory titration allowed for medical optimization, twice-daily doses were far more frequent for the oral form in comparison to intramuscular and pellet therapies and posed a higher risk of missed doses and poorer compliance</u>. </strong>Beyond the results from this trial, future studies should investigate patient satisfaction and side effect profiles in a larger population to support practical adoption by patients and practitioners</em></p></blockquote><p></p>
[QUOTE="madman, post: 261248, member: 13851"] Did you even look over the original paper 8/12/22 from my thread 9/6/22 that I linked up in [B][I]post #4.[/I][/B] Notice the number of patients from week 1--->4--->14--->27. There was a dose titration at week 4 (follow-up visit) in 24% of the patients (N=35). [B][I]*24% of patients required uptitration, while none required downtitration [ATTACH type="full" alt="Screenshot (26889).png"]35393[/ATTACH][/I] Key points: [I]*While the study features of close bloodwork follow-up and mandatory titration allowed for medical optimization, [U]twice-daily doses were far more frequent for the oral form[/U] in comparison to intramuscular and pellet therapies[U] and posed a higher risk of missed doses and poorer compliance[/U] * The reason most often cited for dropout was an [U]unsatisfactory symptom response[/U] *Closer examination of the results revealed that individuals who were previously receiving testosterone pellets or nasal testosterone were [U]more satisfied than patients in the intramuscular testosterone cypionate arm[/U][/I] 3. Results [/B] [I]Of the [B]41 patients enrolled in the study,[/B] 46% were previously on subdermal pellets, 41% on intramuscular injections, and 13% on nasal gels. [B]Testosterone levels increased from a baseline median of 192.0 ng/dl to 738.5 ng/dl (618.3–896.8) at 1 mo, 481.5 ng/dl (349.3–646.3) at 14 wk, and 575.0 ng/dl (336.0–680.5) at 6 mo. Some 24% of patients required uptitration, while none required downtitration. [/B]Patient satisfaction on oral TU in terms of TSQM-9 scores increased from 42.0 (34.0–51.0) on the prior TTh to 49.0 (39.0–57.0) at 14 wk (p = 0.02) and 55.0 (52.0–59.0) at 6 mo (p = 0.0013). Closer examination of the results revealed that individuals who were previously receiving testosterone pellets or nasal testosterone were more satisfied than patients in the intramuscular testosterone cypionate arm. [B]Hypogonadal symptoms in terms of qADAM scores were regarded as similar at 34.4 at 14 wk (p = 0.16) and 35 at 6 mo (p = 0.83) in comparison to 32.5 on prior testosterone therapy. [U]The reason most often cited for dropout was an unsatisfactory symptom response[/U].[/B] We evaluated changes in HCT, prostate-specific antigen, and serum estradiol after testosterone therapy and found that the levels were similar before and after TTh. Of note, phlebotomy was recommended for 16% of the men during the trial.[/I] [B]4. Discussion [/B] [I]This is the first study investigating patient satisfaction among men receiving oral TU who were previously using other forms of TTh. [B]Over the course of the trial, oral TU appeared to lead to greater patient satisfaction in comparison to previous TTh modalities and a similar improvement in hypogonadal symptoms. In addition, oral TU increased serum total testosterone to the normal range (300–1000 ng/dl) in >90% of the men without a difference in side effect profile. [U]While the study features of close bloodwork follow-up and mandatory titration allowed for medical optimization, twice-daily doses were far more frequent for the oral form in comparison to intramuscular and pellet therapies and posed a higher risk of missed doses and poorer compliance[/U]. [/B]Beyond the results from this trial, future studies should investigate patient satisfaction and side effect profiles in a larger population to support practical adoption by patients and practitioners[/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
X (Twitter)
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
PATIENT SATISFACTION WITH ORAL TESTOSTERONE UNDECANOATE IN TESTOSTERONE-DEFICIENT MEN WITH PREVIOUS TESTOSTERONE THERAPY
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top